Assays for parathyroid hormone and their use in patients with end-stage renal disease

被引:1
|
作者
Goodman, WG [1 ]
机构
[1] Univ Calif Los Angeles, Med Ctr, Dept Med, Div Nephrol,Sch Med, Los Angeles, CA 90095 USA
关键词
parathyroid hormone; assay; renal osteodystrophy; end-stage renal disease; bone disease;
D O I
10.1159/000067857
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
New second-generation immunometric PTH assays have been developed. The assays measure full-length biologically active PTH(1-84) exclusively and do not detect amino-terminally-truncated PTH fragments, a feature that distinguishes them from first-generation immunometric PTH assays. Although few studies have been done thus far, second-generation immunometric PTH assays have not been shown to be superior to first-generation assays for the diagnostic assessment of patients with renal osteodystrophy. Plasma PTH levels obtained using first-generation-immunometric PTH assays continue to provide the most definitive guide to the management of renal bone disease because they are supported by abundant bone histology data. Additional work is needed to further characterize the utility of second-generation immunometric PTH assays as predictors of bone histology in patients with ESRD. Copyright (C) 2003 S. Karger AG, Basel.
引用
收藏
页码:118 / 123
页数:6
相关论文
共 50 条
  • [41] End-stage Renal Disease
    Abbasi, Maaz
    Chertow, Glenn
    Hall, Yoshio
    AMERICAN FAMILY PHYSICIAN, 2010, 82 (12) : 1512 - 1514
  • [42] Calcimimetics or vitamin D analogs for suppressing parathyroid hormone in end-stage renal disease: time for a paradigm shift?
    Wetmore, James B.
    Quarles, L. Darryl
    NATURE CLINICAL PRACTICE NEPHROLOGY, 2009, 5 (01): : 24 - 33
  • [43] Calcimimetics or vitamin D analogs for suppressing parathyroid hormone in end-stage renal disease: time for a paradigm shift?
    James B Wetmore
    L Darryl Quarles
    Nature Clinical Practice Nephrology, 2009, 5 : 24 - 33
  • [44] A case of extrapulmonary tuberculosis in a patient with end-stage renal disease with elevated parathyroid hormone-related protein
    Podder, Shreya
    Fleckenstein, Katarina
    Gaudiano, Zehra
    SAGE OPEN MEDICAL CASE REPORTS, 2020, 8
  • [45] Sugammadex use in patients with end-stage renal disease: a historical cohort study
    Paredes, Stephania
    Porter, Steven B.
    Porter, Ivan E., II
    Ross Renew, J.
    CANADIAN JOURNAL OF ANESTHESIA-JOURNAL CANADIEN D ANESTHESIE, 2020, 67 (12): : 1789 - 1797
  • [46] Use of Complementary and Alternative Medicine among Patients with End-Stage Renal Disease
    Birdee, Gurjeet S.
    Phillips, Russell S.
    Brown, Robert S.
    EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE, 2013, 2013
  • [47] Emergency department use by patients with end-stage renal disease in the United States
    Wang, Ningyuan
    Pei, Jiao
    Fan, Hui
    Ali, Yaseen
    Prushinskaya, Anna
    Zhao, Jian
    Zhang, Xingyu
    BMC EMERGENCY MEDICINE, 2021, 21 (01)
  • [48] Parenteral iron use in the management of anemia in end-stage renal disease patients
    Bailie, GR
    Johnson, CA
    Mason, NA
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2000, 35 (01) : 1 - 12
  • [49] Should we use mechanical valves in patients with end-stage renal disease?
    Pai, Vasudev B.
    Tai, Cheh Kuan
    Bhakri, Kunal
    Kolvekar, Shyam
    INTERACTIVE CARDIOVASCULAR AND THORACIC SURGERY, 2012, 15 (02) : 240 - 243
  • [50] Growth hormone in children with chronic renal insufficiency and end-stage renal disease
    Fine, RN
    ENDOCRINOLOGIST, 1998, 8 (03): : 160 - 169